Dacogen sales for 3rd Q and year over year from MGI press release: Dacogen sales rose to $34.6 million. In the third quarter of 2006, its first full period on the market, it brought in $11.9 million.
Vidaza sales for 3rd Q and year over year from PHRM press release: In the U.S., sales of Vidaza totaled $33.3 million in the third quarter of 2007, equal to the same quarter of 2006.
ALL INCREASES IN YoY VIDAZA SALES ($5.7 MILLION) CAME OUTSIDE U.S. Here's why, Pharmion said: Worldwide sales of Vidaza� (azacitidine for injection) totaled $42.3 million in the third quarter of 2007, compared to $36.6 million in the same quarter of 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $9.0 million in the third quarter of 2007, compared to $3.3 million in the third quarter of 2006.
The street will soon digest that Dacogen beats Vidaza when they compete (only in the US). Soon, when J & J gets Dacogen approval in Europe, Dacogen will outsell Vidaza there.
To conclude . . Dacogen has greater market share in US, has grown 300%+ in a year while Vidaza US sales were, as Pharmion says "equal to the same quarter of 2006." This leads me to believe the August Vidaza survival data should not have sent PHRM pps up 40% and SUPG down from $6.40 to $3.93.
His exact words "it is not at all clear that other compounds now undergoing pivotal trials will have similar outcomes" He maybe right ( I doubt it) but its a pretty ballsy statement. Reminds me of the band on the Titanic playing while the ship is sinking. This guy is really arrogrant. Waiting for analysts questions
Thanks for reposting my message Grey. The first statement in the PHRM cc is a spin on Vidaza being the only agent with the "gold standard" of top line survival data. Well, Dacogen will have their "gold standard" survival data out soon. Complete BS. He will eat his words soon. I can't believe he is still spinning Vidaza survival data in such a misleading way.